Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Marcus Neubauer, MD, discusses how practices and administrators can build higher pathway compliance

Marcus Neubauer, MD, VP & Medical Director, McKesson Specialty Health, discusses how practices and administrators can build higher pathway compliance

Published: 13 February 2017

Recent Videos

video

Evolving Immunotherapy Combinations

At ASCO 2017, ZS’s Sharon Karlsberg and Dr. Suzanne Topalian, associate director of the Johns Hopkins Bloomberg-Kimmel Institute for Cancer ...

video

Beyond PD-L1: In Search of Better Biomarkers

ZS’s Sharon Karlsberg sat down with Dr. Suzanne Topalian, Associate Director of the Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, ...

video

Real-World Evidence as a Mechanism for Patient-Centric Care

ZS’s Maria Whitman sat down with Dr. Yousuf Zafar, associate professor of medicine and public policy at Duke University, at ...

video

Real-World Evidence: Can It Drive Differentiation and Demonstrate 'Value'?

ZS’s Maria Whitman sat down with Dr. Yousuf Zafar, associate professor of medicine and public policy at Duke University, at ...

video

Real-World Evidence Compared to Randomized Clinical Trials

ZS’s Maria Whitman sat down with Dr. Yousuf Zafar, associate professor of medicine and public policy at Duke University, at ...

video

Real-World Evidence Today and Tomorrow: The Role of Key Stakeholders

ZS’s Maria Whitman sat down with Dr. Yousuf Zafar, associate professor of medicine and public policy at Duke University, at ...

video

Practical Issues When Treating With Immunotherapy

ZS’s Sharon Karlsberg sat down with Dr. Suzanne Topalian, associate director of the Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, ...

video

Barbara Burtness, MD, on chemotherapy and post-operative radiation in H&C cancers

Dr. Burtness, Disease Aligned Research Team Leader, Head and Neck Cancers Program Co-Director, Developmental Therapeutics Research Program, Yale Cancer Center, ...

video

Aref Al-Kali, MD, regarding the Leukostat test in conjunction with midostaurin

Dr. Al-Kali, Acute Leukemia and Chronic Myeloid Disorders, Mayo Clinic, on whether physicians will adopt the Leukostat test, which was ...

video

Mary Jo Fidler, MD, FASCO, comments on the outlook for immunotherapy combinations in SCLC

Dr. Fidler, Associate Professor, Medical Oncology, Rush University Medical Center, speculates on the future of immunotherapy combinations when treating small ...

Related Videos

video-image

Evolving Immunotherapy Combinations

video-image

Beyond PD-L1: In Search of Better Biomarkers

video-image

Real-World Evidence as a Mechanism for Patient-Centric Care

video-image

Real-World Evidence: Can It Drive Differentiation and Demonstrate 'Value'?

video-image

Real-World Evidence Compared to Randomized Clinical Trials

video-image

Real-World Evidence Today and Tomorrow: The Role of Key Stakeholders

video-image

Practical Issues When Treating With Immunotherapy

video-image

Barbara Burtness, MD, on chemotherapy and post-operative radiation in H&C cancers

video-image

Aref Al-Kali, MD, regarding the Leukostat test in conjunction with midostaurin

video-image

Mary Jo Fidler, MD, FASCO, comments on the outlook for immunotherapy combinations in SCLC

video-image

Mary Jo Fidler, MD, FASCO, considers the biomarker challenges when treating SCLC

video-image

Mary Jo Fidler, MD, FASCO, offers opinion on integrating immunotherapies into treatment of SCLC

video-image

Patricia Goldsmith describes new patient-focused initiatives presented at ASCO 2017

video-image

David Siegel, MD, PhD, on pembrolizumab and lenalidomide in multiple myeloma treatment

video-image

Richard Goldberg, MD, FASCO, on the new FDA indication for pembrolizumab

video-image

Jeffrey Meyerhardt, MD, discusses BRAF+ mutation metastatic CRC and vemurafenib

video-image

Barbara Burtness, MD, on bevacizumab and chemotherapy for treatment of metastatic H&C cancers

video-image

David Siegel, MD, PhD, considers the effectiveness of CAR T-cell therapy in treating MM

video-image

Howard Hochster, MD, on the impact of SWOG 1406 in treating BRAF mutation positive CRC patients

video-image

Jeffrey Meyerhardt, MD, regarding the optimal duration of therapy in stage III colon cancer patients